Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BeOne Medicines Ltd.

Get SEC filing alerts via email and in your feed for BeOne Medicines Ltd.

BEIGF ONC

BeOne Medicines Ltd.

About BeOne Medicines Ltd.

BeiGene, Ltd. is a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative oncology therapies. Its core portfolio includes BRUKINSA, a best-in-class BTK inhibitor for hematologic cancers, and TEVIMBRA, an anti-PD-1 antibody for solid tumors. BeiGene operates integrated research, clinical development, manufacturing, and commercial capabilities, serving diverse markets worldwide with a focus on accessible, affordable cancer treatments and a robust pipeline targeting hematology and solid tumors.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BeOne Medicines Ltd.

1
1
BeOne Medicines Ltd. BeOne Medicines Reports 35.5% Revenue Growth to $1.5 Billion in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
BeOne Medicines Ltd. BeOne Medicines Ltd. Reports 40.2% Revenue Growth and Achieves Profitability in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
BeOne Medicines Ltd. BeOne Medicines Reports 41% Revenue Growth to $1.41 Billion in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BeOne Medicines Ltd. BeOne Medicines Reports 42% Revenue Growth to $1.315 Billion in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BeOne Medicines Ltd. BeiGene Reports 49% Revenue Growth to $1.12 Billion in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BeOne Medicines Ltd. BaiGene Reports 28.2% Revenue Growth to $1.001 Billion in Q3 2024, Net Loss Widens

Via official filing (AI summary) | over 1 year ago | 0 comments